Dr. Parvez M. Lokhandwala, MD, PhD

Dr. Lokhandwala practices at University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System.

Dr. Lokhandwala's NPI, 1043586621, was assigned on March 28, 2012. Dr. Lokhandwala holds Maryland license D82856.

Dr. Lokhandwala's primary practice is University of Maryland Medical Center, at 22 South Greene Street, Baltimore, MD 21201 in Baltimore City. The practice phone is (410) 328-8667.

Dr. Lokhandwala's primary practice is University of Maryland Medical Center in Baltimore, Maryland, part of University of Maryland Medical System. Dr. Lokhandwala is also affiliated with Inova Fairfax Hospital. The medical group on file is Inova Pathology Institute. Dmand AI also links Dr. Lokhandwala to 4 more hospitals, 4 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lokhandwala practices, 7 sites in all. Vendor and product names are available with a free account.

Molecular genetic pathology is Dr. Lokhandwala's primary specialty in the NPI Registry, under taxonomy code 207ZP0007X. Dr. Lokhandwala is licensed in Maryland.

CMS data shows 641 Medicare services from Dr. Lokhandwala across 4 procedure codes in 2024, for 253 Medicare patients. Medicare paid $9,114 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 253 Medicare patients who saw Dr. Lokhandwala in 2024. The largest group is 65 to 74, with 122 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lokhandwala's median patient age at 60, with 62% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 71 out of 100 for Dr. Lokhandwala for performance year 2024, reported as part of a group. Dr. Lokhandwala accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 11 general payments to Dr. Lokhandwala from 1 drug or device company from 2024 to 2025. Consulting fees make up the largest share, 100% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $32,480.